LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics. The goal of the partnership is to create novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile by selectively targeting inactive cytotoxic compounds toward tumor cells. The collaboration combines JPT's proven and long term track record in executing peptide based hit identification and hit-to-lead projects with IUCT's and LEITAT's key expertise in biotechnological synthesis of nucleoside analogs and activity screening studies.

"IUCT and Leitat have been successfully working on the development of new therapies against neoplastic diseases for several years. With JPT we have found a reputable and strong partner that complements our own expertise in creating new targeted anticancer compounds", stated Josep Castells, Executive President at IUCT.

Holger Wenschuh, Managing Director at JPT adds, "The previous scientific work at LEITAT and IUCT lays a solid basis to apply our peptide focused medicinal chemistry experience and capabilities to systematically amend physicochemical properties of the target compounds creating optimized functional profiles."